Circle Cardiovascular Imaging vs Elucid

Elucid's PlaqueIQ is a service. Per its 2024 release, the physician sends CCTA images to Elucid, and trained analysts segment a 3D coronary model before the software quantifies plaque. It is billed to providers per analysis with no public price. Category I CPT 75577 for coronary plaque analysis took effect on January 1, 2026, with a national average of about $1,012 at imaging centers and physician offices per DAIC (currency not stated, and one Elucid release prints $1,021). That rate is the Medicare payment to the performing site and says nothing about Elucid's fee.

FDA decisions are K241524 (September 12, 2024) and K261855 (September 18, 2026), with the cleared claim limited to plaque quantification that supports clinicians.

Circle's cvi42 platform carries an AI Plaque Analysis module, with clearance K251027 for the cvi42 Coronary Plaque Software Application on October 27, 2025. For a cardiology practice that wants a software module rather than an outside analysis service, Elucid is the weaker pick, since Elucid receives the images and has analysts segment them while Circle sells the cvi42 module, which the vendor says integrates with existing systems and workflows. A practice that would rather outsource the segmentation is Elucid's buyer.